ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Monday, November 14, 2016

9:00AM-11:00AM
Abstract Number: 1387
Evaluation of Mild to Moderate SLE Flare in Patients with Childhood-Onset Disease
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 1379
Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 1275
Evaluation of Spine and Tibia Bone Microarchitecture Using Trabecular Bone Score (TBS) and HR-pQCT in Patients with Ankylosing Spondylitis
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI
9:00AM-11:00AM
Abstract Number: 1226
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
Health Services Research - Poster II
9:00AM-11:00AM
Abstract Number: 1373
Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 1366
Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 1921
Evidence for Prevotella Copri As an Immune-Relevant Bacterium in Rheumatoid Arthritis
T Cell Biology and Targets in Autoimmune Disease - Poster Session I
9:00AM-11:00AM
Abstract Number: 1516
Evidence of Labial Salivary Gland Epithelial Cell Activation from Patients with Rheumatoid Arthritis and Sicca Symptomatology
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
9:00AM-11:00AM
Abstract Number: 1891
Excellent Reliability of Semiquantitative Nailfold Capillaroscopy Assessment in a Systemic Sclerosis Cohort – a Pilot Study
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II
9:00AM-11:00AM
Abstract Number: 1883
Exercise Habits and Factors Associated with Exercise in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II
9:00AM-11:00AM
Abstract Number: 1092
Expansion of Age Associated B Cells in Murine Lupus Is Regulated By DEF6 and Its Homologue Swap-70
B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's
9:00AM-11:00AM
Abstract Number: 1088
Expansion of Transitional B Cells in SLE Patients Correlates with Increased Toll-like Receptor 7 Expression
B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's
9:00AM-11:00AM
Abstract Number: 1153
Exploring Perceptions of a Rheumatoid Arthritis Specific Smoking Cessation Programme
Education - ARHP Poster
9:00AM-11:00AM
Abstract Number: 1477
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
9:00AM-11:00AM
Abstract Number: 1484
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications
  • «Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 68
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology